Financials CHA Vaccine Research Institute

Equities

A261780

KR7261780001

Biotechnology & Medical Research

End-of-day quote Korea S.E. 06:00:00 2024-05-13 pm EDT 5-day change 1st Jan Change
4,855 KRW +0.62% Intraday chart for CHA Vaccine Research Institute -2.61% -14.07%

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 293,364 131,749 151,036
Enterprise Value (EV) 1 252,660 97,624 116,467
P/E ratio -14.1 x -19.6 x -86 x
Yield - - -
Capitalization / Revenue 587 x 734 x 514 x
EV / Revenue 505 x 544 x 396 x
EV / EBITDA -43.3 x -16.1 x -19.8 x
EV / FCF -41.9 x -14.4 x -11.4 x
FCF Yield -2.39% -6.96% -8.8%
Price to Book 7.41 x 3.95 x 4.26 x
Nbr of stocks (in thousands) 26,429 26,429 26,732
Reference price 2 11,100 4,985 5,650
Announcement Date 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 500 179.5 294.1
EBITDA 1 -5,839 -6,052 -5,886
EBIT 1 -6,085 -6,469 -6,419
Operating Margin -1,216.93% -3,604.36% -2,182.53%
Earnings before Tax (EBT) 1 -18,420 -6,715 -2,103
Net income 1 -18,420 -6,715 -1,749
Net margin -3,684.01% -3,741.36% -594.82%
EPS 2 -789.6 -254.1 -65.72
Free Cash Flow 1 -6,029 -6,799 -10,251
FCF margin -1,205.81% -3,787.96% -3,485.32%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - - -
Net Cash position 1 40,704 34,125 34,569
Leverage (Debt/EBITDA) - - -
Free Cash Flow 1 -6,029 -6,799 -10,251
ROE (net income / shareholders' equity) -89.4% -18.4% -5.09%
ROA (Net income/ Total Assets) -8.35% -6.4% -7.56%
Assets 1 220,534 104,949 23,152
Book Value Per Share 2 1,499 1,262 1,325
Cash Flow per Share 2 150.0 90.30 221.0
Capex 1 680 447 279
Capex / Sales 135.91% 249.27% 94.71%
Announcement Date 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. A261780 Stock
  4. Financials CHA Vaccine Research Institute
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW